Search

Displaying results 2141 - 2150 of 8573 in total
  1. Drug

    Methoxamine

    go.drugbank.com/drugs/DB00723
    ApprovedInvestigationalWithdrawn

    It has little if any direct effect on the central nervous system.

  2. Drug

    Ipilimumab

    go.drugbank.com/drugs/DB06186
    ApprovedInvestigational

    [A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex.[L12126] Ipilimumab was granted FDA approval on 25 March 2011.[L12126]

    Products: YERVOY 200MG/40ML IV INFUZYONLUK ÇOZELTI KONSANTRESI ICEREN FLAKON, 1 ADET
  3. Drug

    Stanozolol

    go.drugbank.com/drugs/DB06718
    ApprovedVet approved

    Stanozolol is derived from testosterone, and has been abused by several high profile professional athletes.

  4. Drug

    DaxibotulinumtoxinA

    go.drugbank.com/drugs/DB17929
    ApprovedInvestigational

    [L47865] On August 14, 2023, the drug was also approved for the treatment of cervical dystonia. … [A261075, L47860] DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines.

  5. Drug

    Tacrine

    go.drugbank.com/drugs/DB00382
    ApprovedWithdrawn

    Tacrine has been discontinued for the United States market. … A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous

  6. Drug

    Leronlimab

    go.drugbank.com/drugs/DB05941
    Investigational

    [L12684] It was first described in the literature in 2001.[A3922] This antibody binds to CCR5, which may be useful in treating HIV, cancers, and severely ill COVID-19 patients.[A192846,A192858,L12684]

  7. Drug

    Latanoprostene bunod

    go.drugbank.com/drugs/DB11660
    Approved

    Latanoprostene Bunod has been used in trials studying the treatment of Glaucoma, Ocular Hypertension, Open-Angle Glaucoma, Open Angle Glaucoma, and Intraocular Pressure. … As of November 2, 2017 the FDA approved Bausch + Lomb's Vyzulta (latanoprostene bunod opthalmic solution), 0.024% for the indication of reducing intraocular pressure in patients with open-angle glaucoma

  8. Drug

    Ixazomib

    go.drugbank.com/drugs/DB09570
    ApprovedInvestigational

    [L51244] It was also investigated in other hematological malignancies as well as other conditions, such as systemic light chain (AL) amyloidosis, graft-versus-host disease, and lupus nephritis. … [A264319] It was later approved by Health Canada on August 3, 2016,[L51239] and by the EMA on November 21, 2016.

  9. Drug

    Lazertinib

    go.drugbank.com/drugs/DB16216
    ApprovedInvestigational

    [A264289] It was approved by the FDA on August 19, 2024.[L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184] … [A264299, A264304] Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of _EGFR_ T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations.

  10. Drug

    Molnupiravir

    go.drugbank.com/drugs/DB15661
    Investigational

    [A193029] Recent studies have shown molnupiravir inhibits replication of human and bat coronaviruses, including SARS-CoV-2, in mice and human airway epithelial cells. … [A193014] Molnupiravir was granted approval by the UK's Medicines and Health products Regulatory Agency (MHRA) on 4 November 2021 to prevent severe outcomes such as hospitalization and death due to

    Products: LAGEVRIO® 200MG CAPSULAS, Lagevrio 200mg Hard Capsule